NASDAQ:PHAS PhaseBio Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding PhaseBio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.66 +0.01 (+1.54%) (As of 06/29/2022 12:00 AM ET) Add Compare Share Today's Range$0.59▼$0.6750-Day Range$0.52▼$1.3952-Week Range$0.50▼$4.10Volume220,002 shsAverage Volume566,484 shsMarket Capitalization$32.00 millionP/E RatioN/ADividend YieldN/APrice Target$12.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PHAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PhaseBio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address PHAS Stock Forecast (MarketRank)Overall MarketRank™2.01 out of 5 starsMedical Sector595th out of 1,432 stocksPharmaceutical Preparations Industry271st out of 685 stocksAnalyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingPhaseBio Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.50, PhaseBio Pharmaceuticals has a forecasted upside of 1,801.7% from its current price of $0.66.Amount of Analyst CoveragePhaseBio Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 4.3 Community Rank Outperform VotesPhaseBio Pharmaceuticals has received 117 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPhaseBio Pharmaceuticals has received 68 “underperform” votes. (Add your “underperform” vote.)Community SentimentPhaseBio Pharmaceuticals has received 63.24% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about PhaseBio Pharmaceuticals and other stocks. Vote “Outperform” if you believe PHAS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PHAS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPhaseBio Pharmaceuticals does not currently pay a dividend.Dividend GrowthPhaseBio Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PhaseBio Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,886.00 in company stock.Percentage Held by InsidersOnly 9.90% of the stock of PhaseBio Pharmaceuticals is held by insiders.Percentage Held by Institutions57.43% of the stock of PhaseBio Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for PhaseBio Pharmaceuticals are expected to grow in the coming year, from ($1.64) to ($1.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PhaseBio Pharmaceuticals is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PhaseBio Pharmaceuticals is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About PhaseBio Pharmaceuticals (NASDAQ:PHAS)PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.Read More PHAS Stock News HeadlinesJune 29, 2022 | americanbankingnews.comPhaseBio Pharmaceuticals (NASDAQ:PHAS) Trading Up 2.4%May 16, 2022 | benzinga.comPhaseBio Pharmaceuticals: Q1 Earnings InsightsMay 16, 2022 | seekingalpha.comPhaseBio Pharmaceuticals GAAP EPS of -$0.23 beats by $0.43May 16, 2022 | seekingalpha.comPhaseBio to seek FDA approval for clotting agent in 4Q 2022May 16, 2022 | finance.yahoo.comPhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business HighlightsMay 16, 2022 | finance.yahoo.comPhaseBio Pharmaceuticals (PHAS) Reports Q1 Loss, Misses Revenue EstimatesMay 14, 2022 | seekingalpha.comPHAS PhaseBio Pharmaceuticals, Inc.April 18, 2022 | finance.yahoo.comNeedham Estimates PhaseBio Pharma's Bentracimab Market Opportunity Of Up To $1.5BApril 7, 2022 | nz.finance.yahoo.comPhaseBio Pharmaceuticals to Participate in the 21st Annual Needham Healthcare ConferenceApril 4, 2022 | seekingalpha.comPhaseBio reports full results of phase 2b trial of bentracimab to reverse ticagrelor's antiplatelet activityApril 4, 2022 | finance.yahoo.comPhaseBio Announces Positive Results from Phase 2b Trial for BentracimabMarch 28, 2022 | benzinga.comNeedham Maintains Buy on PhaseBio Pharmaceuticals, Lowers Price Target to $10March 25, 2022 | benzinga.comLooking Into PhaseBio Pharmaceuticals's Return On Capital EmployedSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PHAS CUSIPN/A CIK1169245 Webwww.phasebio.com Phone(610) 981-6500FaxN/AEmployees60Year FoundedN/ACompany Calendar Last Earnings5/16/2022Today6/30/2022Next Earnings (Estimated)8/11/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$12.50 High Stock Price Forecast$15.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+1,801.7%Consensus RatingBuy Rating Score (0-4)3 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-131.07 million Net Margins-1,049.18% Pretax Margin-1,034.57% Return on EquityN/A Return on Assets-165.52% Debt Debt-to-Equity RatioN/A Current Ratio1.27 Quick Ratio1.27 Sales & Book Value Annual Sales$10.83 million Price / Sales2.96 Cash FlowN/A Price / Cash FlowN/A Book Value($1.93) per share Price / Book-0.34Miscellaneous Outstanding Shares48,691,000Free Float43,871,000Market Cap$32.00 million OptionableNot Optionable Beta2.02 PhaseBio Pharmaceuticals Frequently Asked Questions Should I buy or sell PhaseBio Pharmaceuticals stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PhaseBio Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PhaseBio Pharmaceuticals stock. View analyst ratings for PhaseBio Pharmaceuticals or view top-rated stocks. What is PhaseBio Pharmaceuticals' stock price forecast for 2022? 3 Wall Street analysts have issued 12-month price objectives for PhaseBio Pharmaceuticals' stock. Their PHAS stock forecasts range from $10.00 to $15.00. On average, they predict PhaseBio Pharmaceuticals' share price to reach $12.50 in the next year. This suggests a possible upside of 1,801.7% from the stock's current price. View analysts' price targets for PhaseBio Pharmaceuticals or view top-rated stocks among Wall Street analysts. How has PhaseBio Pharmaceuticals' stock performed in 2022? PhaseBio Pharmaceuticals' stock was trading at $2.61 at the start of the year. Since then, PHAS shares have decreased by 74.8% and is now trading at $0.6573. View the best growth stocks for 2022 here. When is PhaseBio Pharmaceuticals' next earnings date? PhaseBio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for PhaseBio Pharmaceuticals. How were PhaseBio Pharmaceuticals' earnings last quarter? PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) announced its quarterly earnings data on Monday, May, 16th. The company reported ($0.23) earnings per share for the quarter, beating analysts' consensus estimates of ($0.67) by $0.44. The firm had revenue of $0.12 million for the quarter, compared to the consensus estimate of $5.83 million. View PhaseBio Pharmaceuticals' earnings history. Who are PhaseBio Pharmaceuticals' key executives? PhaseBio Pharmaceuticals' management team includes the following people: Mr. Jonathan P. Mow MBA, Pres, CEO & Director (Age 57, Pay $894.66k)Mr. John P. Sharp CPA, Chief Financial Officer (Age 57, Pay $573.34k)Dr. John S. Lee M.D., Ph.D., Chief Medical Officer (Age 54, Pay $648.88k)Ms. Susan Elizabeth Arnold Ph.D., Sr. VP of Technical Operations (Age 47)Mr. Kristopher L. Hanson, SVP, Gen. Counsel & Corp. Sec. (Age 50)Mr. Glen G. Burkhardt, Sr. VP of HR (Age 63) (LinkedIn Profile)Ms. Lauren Richardson, Global Head of Regulatory Affairs & Quality AssuranceMr. Jonathan J. Birchall, Chief Commercial Officer (Age 53) Who are some of PhaseBio Pharmaceuticals' key competitors? Some companies that are related to PhaseBio Pharmaceuticals include Longeveron (LGVN), ProMetic Life Sciences (PFSCF), Satsuma Pharmaceuticals (STSA), Enochian Biosciences (ENOB), MediciNova (MNOV), Nanobiotix (NBTX), Endo International (ENDP), CytomX Therapeutics (CTMX), Otonomy (OTIC), Actinium Pharmaceuticals (ATNM), Actinium Pharmaceuticals (ATNM), Applied Molecular Transport (AMTI), Praxis Precision Medicines (PRAX), ContraFect (CFRX) and Homology Medicines (FIXX). View all of PHAS's competitors. What other stocks do shareholders of PhaseBio Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other PhaseBio Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), Selecta Biosciences (SELB), Sorrento Therapeutics (SRNE), Amarin (AMRN), Vaxart (VXRT) and Agile Therapeutics (AGRX). When did PhaseBio Pharmaceuticals IPO? (PHAS) raised $66 million in an initial public offering (IPO) on Thursday, October 18th 2018. The company issued 5,000,000 shares at $12.50-$14.00 per share. Citigroup, Cowen and Stifel acted as the underwriters for the IPO and Needham was co-manager. What is PhaseBio Pharmaceuticals' stock symbol? PhaseBio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAS." How do I buy shares of PhaseBio Pharmaceuticals? Shares of PHAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is PhaseBio Pharmaceuticals' stock price today? One share of PHAS stock can currently be purchased for approximately $0.66. How much money does PhaseBio Pharmaceuticals make? PhaseBio Pharmaceuticals (NASDAQ:PHAS) has a market capitalization of $32.00 million and generates $10.83 million in revenue each year. The company earns $-131.07 million in net income (profit) each year or ($2.39) on an earnings per share basis. How many employees does PhaseBio Pharmaceuticals have? PhaseBio Pharmaceuticals employs 60 workers across the globe. How can I contact PhaseBio Pharmaceuticals? PhaseBio Pharmaceuticals' mailing address is 1 Great Valley Parkway Suite 30, Malvern PA, 19355. The official website for PhaseBio Pharmaceuticals is www.phasebio.com. The company can be reached via phone at (610) 981-6500 or via email at [email protected]. This page (NASDAQ:PHAS) was last updated on 6/30/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here